This year’s most read articles on respiratory cover topics on long-term health effects of COVID-19, adolescent vaping, and more.
The top 5 most-read respiratory articles and interviews on AJMC.com this year look at the most pressing issues, including long-term COVID-19, pneumonia, and long-term health effects of vaping.
Here are the most-viewed respiratory pieces in 2022.
5. Short-Course Antibiotic Therapy for Community-Acquired Pneumonia as Effective as Long-Course Therapy
A study published in the journal Clinical Microbiology and Infection found that short-course antibiotic therapy was just as effective as long-course therapy when comparing results in hospitalized patients with mild or moderate community-acquired pneumonia. Minimizing antibiotic use with short-course therapy addresses concerns regarding antimicrobial resistance to antibiotics. The real-world findings added to previous research, which mainly came from randomized controlled trials.
4. Nutrition, Pneumonia Severity May Predict Life Expectancy From Aspiration Pneumonia
Poor nutritional status and worse severity of pneumonia were associated with higher mortality rates in aspiration pneumonia, according to a study published in The Clinical Respiratory Journal. Additionally, men were found to have lower survival rates compared with women. When evaluating these risk factors for 90-day survival, the researchers found the non-survival group had higher disease severity, as measured by increased inflammation levels of C-reactive protein, white blood cell count, and dehydration and significantly higher nutritional disorders.
3. Vaping Injuries Associated With Long-term Respiratory Problems, Study Finds
Patients with e-cigarette or vaping-associated lung injury (EVALI) were found to have a higher risk of developing a disability that would keep them being able to work or pay bills, according to a study presented at the American Thoracic Society Meeting. Higher risk of cognitive impairment, depression, anxiety, and posttraumatic stress were found in patients within 1 year after EVALI.
2. COVID-19 Survivors at Increased Risk for Pulmonary Embolism, Respiratory Symptoms
People who were exposed to and infected with SARS-CoV-2 have twice the risk of developing pulmonary embolism or respiratory conditions, researchers found. When evaluating case patients to control patients, 38% of case patients experienced an incidence of pulmonary embolism or respiratory symptoms compared with 16% of control patients. The report was published in the CDC's Morbidity and Mortality Weekly Report.
1. Frequent Productive Cough Associated With Worse Outcomes in Asthma, COPD
Frequent productive cough was found to be an indicator of adverse outcomes for patients with asthma and/or chronic obstructive pulmonary disease (COPD). The prevalence of frequent productive cough increased with higher disease severity and was linked with significant disease burden. The study was published in in Respiratory Medicine.
Exploring the Potential of Machine Learning in Optimizing Respiratory Failure Treatment
August 9th 2025Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
Read More
Preventing Respiratory Illness and Death Through Tighter Air Quality Standards
June 1st 2021On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
Listen
RSV's Impact on Heart Health Emphasizes Broader Risks, Vaccination Importance for Older Adults
July 23rd 2025Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population regardless of their preexisting health conditions.
Read More
Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control
July 3rd 2025Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
Read More